1451 related articles for article (PubMed ID: 18662762)
1. Mono-N-carboxymethyl chitosan (MCC) and N-trimethyl chitosan (TMC) nanoparticles for non-invasive vaccine delivery.
Sayin B; Somavarapu S; Li XW; Thanou M; Sesardic D; Alpar HO; Senel S
Int J Pharm; 2008 Nov; 363(1-2):139-48. PubMed ID: 18662762
[TBL] [Abstract][Full Text] [Related]
2. TMC-MCC (N-trimethyl chitosan-mono-N-carboxymethyl chitosan) nanocomplexes for mucosal delivery of vaccines.
Sayin B; Somavarapu S; Li XW; Sesardic D; Senel S; Alpar OH
Eur J Pharm Sci; 2009 Nov; 38(4):362-9. PubMed ID: 19733658
[TBL] [Abstract][Full Text] [Related]
3. Mechanistic study of the adjuvant effect of biodegradable nanoparticles in mucosal vaccination.
Slütter B; Plapied L; Fievez V; Sande MA; des Rieux A; Schneider YJ; Van Riet E; Jiskoot W; Préat V
J Control Release; 2009 Sep; 138(2):113-21. PubMed ID: 19445980
[TBL] [Abstract][Full Text] [Related]
4. N-trimethyl chitosan (TMC) nanoparticles loaded with influenza subunit antigen for intranasal vaccination: biological properties and immunogenicity in a mouse model.
Amidi M; Romeijn SG; Verhoef JC; Junginger HE; Bungener L; Huckriede A; Crommelin DJ; Jiskoot W
Vaccine; 2007 Jan; 25(1):144-53. PubMed ID: 16973248
[TBL] [Abstract][Full Text] [Related]
5. Relationship between structure and adjuvanticity of N,N,N-trimethyl chitosan (TMC) structural variants in a nasal influenza vaccine.
Hagenaars N; Verheul RJ; Mooren I; de Jong PH; Mastrobattista E; Glansbeek HL; Heldens JG; van den Bosch H; Hennink WE; Jiskoot W
J Control Release; 2009 Dec; 140(2):126-33. PubMed ID: 19712713
[TBL] [Abstract][Full Text] [Related]
6. Efficient induction of immune responses through intradermal vaccination with N-trimethyl chitosan containing antigen formulations.
Bal SM; Slütter B; van Riet E; Kruithof AC; Ding Z; Kersten GF; Jiskoot W; Bouwstra JA
J Control Release; 2010 Mar; 142(3):374-83. PubMed ID: 19932723
[TBL] [Abstract][Full Text] [Related]
7. Nasal vaccination with N-trimethyl chitosan and PLGA based nanoparticles: nanoparticle characteristics determine quality and strength of the antibody response in mice against the encapsulated antigen.
Slütter B; Bal S; Keijzer C; Mallants R; Hagenaars N; Que I; Kaijzel E; van Eden W; Augustijns P; Löwik C; Bouwstra J; Broere F; Jiskoot W
Vaccine; 2010 Aug; 28(38):6282-91. PubMed ID: 20638455
[TBL] [Abstract][Full Text] [Related]
8. In vitro and in vivo study of N-trimethyl chitosan nanoparticles for oral protein delivery.
Chen F; Zhang ZR; Yuan F; Qin X; Wang M; Huang Y
Int J Pharm; 2008 Feb; 349(1-2):226-33. PubMed ID: 17825506
[TBL] [Abstract][Full Text] [Related]
9. Immunoadjuvant potential of cross-linked dextran microspheres mixed with chitosan nanospheres encapsulated with tetanus toxoid.
Pirouzmand H; Khameneh B; Tafaghodi M
Pharm Biol; 2017 Dec; 55(1):212-217. PubMed ID: 27927058
[TBL] [Abstract][Full Text] [Related]
10. Administration routes affect the quality of immune responses: A cross-sectional evaluation of particulate antigen-delivery systems.
Mohanan D; Slütter B; Henriksen-Lacey M; Jiskoot W; Bouwstra JA; Perrie Y; Kündig TM; Gander B; Johansen P
J Control Release; 2010 Nov; 147(3):342-9. PubMed ID: 20727926
[TBL] [Abstract][Full Text] [Related]
11. Development and characterization of chitosan coated poly-(ɛ-caprolactone) nanoparticulate system for effective immunization against influenza.
Gupta NK; Tomar P; Sharma V; Dixit VK
Vaccine; 2011 Nov; 29(48):9026-37. PubMed ID: 21939718
[TBL] [Abstract][Full Text] [Related]
12. Permeation enhancer effect of chitosan and chitosan derivatives: comparison of formulations as soluble polymers and nanoparticulate systems on insulin absorption in Caco-2 cells.
Sadeghi AM; Dorkoosh FA; Avadi MR; Weinhold M; Bayat A; Delie F; Gurny R; Larijani B; Rafiee-Tehrani M; Junginger HE
Eur J Pharm Biopharm; 2008 Sep; 70(1):270-8. PubMed ID: 18492606
[TBL] [Abstract][Full Text] [Related]
13. Induction of systemic and mucosal immune responses by intranasal administration of alginate microspheres encapsulated with tetanus toxoid and CpG-ODN.
Tafaghodi M; Sajadi Tabassi SA; Jaafari MR
Int J Pharm; 2006 Aug; 319(1-2):37-43. PubMed ID: 16701972
[TBL] [Abstract][Full Text] [Related]
14. Chitosan nanoparticles encapsulated vesicular systems for oral immunization: preparation, in-vitro and in-vivo characterization.
Jain S; Sharma RK; Vyas SP
J Pharm Pharmacol; 2006 Mar; 58(3):303-10. PubMed ID: 16536896
[TBL] [Abstract][Full Text] [Related]
15. Quillaja saponaria extract as mucosal adjuvant with chitosan functionalized gold nanoparticles for mucosal vaccine delivery: stability and immunoefficiency studies.
Barhate G; Gautam M; Gairola S; Jadhav S; Pokharkar V
Int J Pharm; 2013 Jan; 441(1-2):636-42. PubMed ID: 23117021
[TBL] [Abstract][Full Text] [Related]
16. Development of a novel adjuvanted nasal vaccine: C48/80 associated with chitosan nanoparticles as a path to enhance mucosal immunity.
Bento D; Staats HF; Gonçalves T; Borges O
Eur J Pharm Biopharm; 2015 Jun; 93():149-64. PubMed ID: 25818119
[TBL] [Abstract][Full Text] [Related]
17. Alginate coated chitosan nanoparticles are an effective subcutaneous adjuvant for hepatitis B surface antigen.
Borges O; Silva M; de Sousa A; Borchard G; Junginger HE; Cordeiro-da-Silva A
Int Immunopharmacol; 2008 Dec; 8(13-14):1773-80. PubMed ID: 18801462
[TBL] [Abstract][Full Text] [Related]
18. Preparation and characterization of folate conjugated N-trimethyl chitosan nanoparticles as protein carrier targeting folate receptor: in vitro studies.
Zheng Y; Cai Z; Song X; Chen Q; Bi Y; Li Y; Hou S
J Drug Target; 2009 May; 17(4):294-303. PubMed ID: 19255895
[TBL] [Abstract][Full Text] [Related]
19. Novel chitosan derivative nanoparticles enhance the immunogenicity of a DNA vaccine encoding hepatitis B virus core antigen in mice.
Jiang L; Qian F; He X; Wang F; Ren D; He Y; Li K; Sun S; Yin C
J Gene Med; 2007 Apr; 9(4):253-64. PubMed ID: 17397104
[TBL] [Abstract][Full Text] [Related]
20. Enhanced mucosal immune responses against tetanus toxoid using novel delivery system comprised of chitosan-functionalized gold nanoparticles and botanical adjuvant: characterization, immunogenicity, and stability assessment.
Barhate G; Gautam M; Gairola S; Jadhav S; Pokharkar V
J Pharm Sci; 2014 Nov; 103(11):3448-3456. PubMed ID: 25219511
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
